OR WAIT 15 SECS
Boehringer Ingelheim announced that it would collaborate with Yale University to research novel therapeutic targets in immune-modulation.
On January 13, 2015, Boehringer Ingelheim (BI) announced that it would collaborate with Yale University to research novel therapeutic targets in immune-modulation, or treatments aimed at harnessing a patient’s immune system for tumor control, stabilization, and eradication of the disease, according to the British Journal of Cancer. BI will provide Yale with research funding for an agreed upon number of projects, while working closely with the Yale scientists to advance the research. The terms of the agreement also give BI the option to obtain an exclusive license from Yale for all of the programs.
"This collaboration will help us to identify important pathways, and what the biological application of modulating those pathways will be. We will investigate whether these new pathways could become future drug targets,” said Lieping Chen, MD, United Technologies chair in cancer research, professor of immunobiology and director of cancer immunology at the Yale Cancer Center, Yale University School of Medicine, in a press release.
Source: Boehringer Ingelheim